ProCE Banner Activity

Expert Q&A – Bridging the Gap in Pulmonary Arterial Hypertension in Connective Tissue Disease: Promoting Consistent Screening and Management Regimens

Text Module

During PCE's recent Pulmonary Bootcamp, attendees had the chance to ask our expert faculty a variety of questions related to the topic of connective tissue disease in pulmonary arterial hypertension (CTD-PAH). Here, Kristin B. Highland, MD, MSCR, director of the Rheumatic Lung Disease Program at Cleveland Clinic, and Martha Kingman, FNP-C, DNP, advanced practice provider in the Pulmonary Hypertension Clinic at University of Texas Southwestern Medical School in Dallas, provide answers to the questions addressed during the live presentation. We hope you will find their responses relevant to your practice.

In Partnership With the Association of Pulmonary Advanced Practice Providers

APAPP Logo

Released: December 10, 2021

Expiration: December 09, 2022

No longer available for credit.

Share

Faculty

Kristin B. Highland

Kristin B. Highland, MD, MSCR

Director
Rheumatic Lung Disease Program
Cleveland Clinic
Cleveland, Ohio

Martha Kingman

Martha Kingman, FNP-C, DNP

Nurse Practitioner
Pulmonary Hypertension Clinic
University of Texas Southwestern Medical Center
Dallas, Texas

Acknowledgement

This program is cosupported by educational grants from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson; Genentech, a member of the Roche Group; GlaxoSmithKline; Jazz Pharmaceuticals, Inc.; and Mylan Specialty L.P.

This activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.

Disclosure

Dr Highland: contracted research: Gossamer Bio, Reata, Viela Bio; contracted research/consulting fees: Acceleron; contracted research/consulting fees/fees for non-CME/CE services: Boehringer Ingelheim, United Therapeutics; contracted research/fees for non-CME/CE services: Bayer.

Dr Kingman: consulting fees: Actelion/Johnson & Johnson, Bayer, United Therapeutics.

Additional Information

Program Medium

This program has been made available online.